BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT)
Insiders here have filed 7 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$182.1M
- Net margin
- —
Little or no net debt.
- Total debt
- $2.5M
- Cash
- $54.1M
- Debt / equity
- 0.01
Comfortably covers what is due within a year.
- Current assets
- $242.4M
- Current liabilities
- $51.6M
- Current ratio
- 4.69
Consumes cash and must keep raising it.
- Operating cash flow
- -$193.1M
- Free cash flow
- -$193.8M
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 0.1M
- Share growth (1y)
- 59.5%
- Cash runway
- 3 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
BBOT Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 186.00 K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -186.00 K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 10.96 M | 6.38 M | 5.33 M | 14.13 M | 2.65 M | 2.50 M |
| R&D Expense | 49.23 M | 39.80 M | 38.07 M | 35.05 M | 27.44 M | 20.64 M |
| Operating Expenses | 60.19 M | 45.99 M | 43.41 M | 49.18 M | 30.09 M | 23.14 M |
| Operating Income | -60.19 M | -46.18 M | -43.41 M | -49.18 M | -30.09 M | -23.14 M |
| Pretax Income | -56.45 M | -42.11 M | -38.80 M | -44.76 M | -28.43 M | -22.05 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -56.45 M | -42.11 M | -38.80 M | -44.76 M | -28.43 M | -22.05 M |
| EPS (Basic) | -705.20 | -526.11 | -0.48 | -1.03 | -566.46 | -54.23 |
| EPS (Diluted) | -705.20 | -1.35 | -1.25 | -1.90 | -1.21 | -0.94 |
| Shares Outstanding | 80.05 K | 80.03 K | 79.99 M | 43.49 M | 50.20 K | 406.72 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.